Associated tags: National Research Council, NIH, NRC, COVID-19, Bangladesh Technical Education Board, Infection, Research, Bacteria, Health, Pharmaceutical, Biotechnology, NYSE, Infectious Diseases, Oragene, Pharmaceutical industry, Vaccine, FDA, Immunization, Hand, Communication, Science, Patent
Locations: QUEBEC, NEVADA, AURORA, AVALON, COLORADO, TAMPA, FL, US, IV, FANA, MA, FALLS, AUSTRALIA, NORTH AMERICA, NEW ZEALAND
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
Health,
COVID-19,
Infectious Diseases,
Saint,
FDA,
Lead,
Infection,
Immunization,
Vaccine,
Wharton School of the University of Pennsylvania,
University,
Acquisition,
Â,
NASDAQ,
Marketing,
COVID-19,
Biotechnology Innovation Organization,
National,
MBA,
National Research Council,
Board of directors,
Director,
Merck & Co.,
Health care,
Company,
Research,
Patent,
NIH,
Bacteria,
Chairperson,
Wendell Pritchett,
U.S. Securities and Exchange Commission,
Merck,
Private Securities Litigation Reform Act,
Communication,
Hand,
Novartis,
CEO,
Leadership,
NRC,
Program,
NYSE,
Old Dominion University,
Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc.,
Growth,
GSK,
Pharmaceutical industry,
Management,
Global,
Board,
Oragene Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company), a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Kimberly M. Murphy, member of the Board of Directors, as President and Chief Executive Officer effective June 23, 2022.
Key Points:
- Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company), a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Kimberly M. Murphy, member of the Board of Directors, as President and Chief Executive Officer effective June 23, 2022.
- As a Board Member, Ms. Murphys extensive experience in the vaccine industry has provided valuable insight for Oragenics corporate and development strategies.
- We are excited to have her strategic vision further implemented serving as President and Chief Executive Officer.
- I am honored to be appointed as the President and Chief Executive Officer and excited to create additional meaningful impact to accelerate growth and lead our team, said Kimberly Murphy, CEO.
Biotechnology,
Infectious Diseases,
COVID-19,
Health,
Pharmaceutical,
Coronavirus,
Viral load,
Research,
Immunization,
BioRxiv,
Patent,
National Research Council,
Scientific Reports,
GLP,
NIH,
Blood,
Immunoglobulin G,
NRC,
Immunoglobulin A,
U.S. Securities and Exchange Commission,
Vaccine,
FDA,
Hand,
Private Securities Litigation Reform Act,
Infection,
NYSE,
COVID-19,
Antibody,
Toxicology,
Hamster,
Bacteria,
Preprint,
Communication,
Pharmaceutical industry,
Mouse,
Oragene,
Nature The publication, available [ https://rdcu.be/cPyZF ] and titled Intranasal Immunization with a Proteosome-Adjuvanted SARS-CoV2 Spike Protein-Based Vaccine is Immunogenic and Efficacious in Mice & Hamsters, concluded that Oragenics intranasal vaccine candidate, NT-CoV2-1, warrants further development as a novel SARS-CoV-2 vaccine.
Key Points:
- The publication, available [ https://rdcu.be/cPyZF ] and titled Intranasal Immunization with a Proteosome-Adjuvanted SARS-CoV2 Spike Protein-Based Vaccine is Immunogenic and Efficacious in Mice & Hamsters, concluded that Oragenics intranasal vaccine candidate, NT-CoV2-1, warrants further development as a novel SARS-CoV-2 vaccine.
- Were proud to have our innovative intranasal vaccine candidate studies published in a reputable, peer-reviewed scientific journal, and believe this heightened recognition underscores the need for vaccines that address the limitations of currently available options.
- These published data, and our on-going GLP toxicology study will be part of our preclinical data package seeking permission to enter our first-in human clinical trials, said Frederick W. Telling, Ph.D., Executive Chairman of Oragenics.
- Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus.
Health,
Infectious Diseases,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Immunoglobulin A,
Severe acute respiratory syndrome coronavirus 2,
Death,
Hamster,
RNA transfection,
Degenerative disease,
Rabbit,
Annual general meeting,
Toxicology,
Immortalised cell line,
Hospital,
Epithelium,
Nasal cavity,
Infection,
Vaccine,
GLP,
COVID-19,
CHO,
Executive,
Trial of the century,
Vaccination,
NIH,
Research,
Mouse,
Efficiency,
Transport,
Refrigeration,
Immunization,
CTA,
Immunity,
Compliance,
Program,
Technology,
Safety,
Temperature,
Nose,
Health Canada,
National,
Administration,
Synthetic control method,
NRC,
Laboratory,
National Research Council,
NYSE,
Pharmaceutical industry,
Oragene,
IND I thank you for your continued support of Oragenics and our vision, and am delighted to report on our recent progress.
Key Points:
- I thank you for your continued support of Oragenics and our vision, and am delighted to report on our recent progress.
- In previous letters I affirmed the strategic direction Oragenics is taking and discussed our commitment to the speedy yet prudent execution of our development work.
- Through this letter I aim to provide clarity on the opportunity, rationale and pathway toward human clinical testing.
- On behalf of the Oragenics Board of Directors, I thank you for your continued support and look forward to keeping you apprised of our ongoing progress.
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
Health,
Infectious Diseases,
Clinical Trials,
Patent,
GlaxoSmithKline,
IND,
NIH,
U.S. Securities and Exchange Commission,
COVID-19,
Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc.,
NASDAQ,
Research,
Bacteria,
Private Securities Litigation Reform Act,
GSK,
NRC,
Merck,
Infection,
Congress,
Vaccine,
Company,
Communication,
Hand,
NYSE,
Coronavirus,
Viral load,
FDA,
Immunization,
GLP,
Pharmaceutical industry,
Oragene The NT-CoV2-1 intranasal vaccine program approach is focused on patient-friendly administration, reducing transmission through a mucosal immune response, and to provide long-lasting protection.
Key Points:
- The NT-CoV2-1 intranasal vaccine program approach is focused on patient-friendly administration, reducing transmission through a mucosal immune response, and to provide long-lasting protection.
- As a recombinant protein and adjunctive vaccine, NT-CoV2-1 is differentiated compared to live-attenuated intranasal vaccines candidates that may cause greater side effects and harder to produce.
- Ms. Murphy joined Oragenics Board of Directors in 2020 and actively provides vital insight to the Companys strategic corporate and development objectives.
- Please contact [email protected] if you are interested in meeting with Ms. Murphy at the World Vaccine Congress in Washington D.C.
Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms.
Research,
Infectious Diseases,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
General Health,
Other Science,
Science,
Patent,
NT,
NYSE,
GLP,
Bacteria,
IND,
Vaccine,
Research,
NRC,
Severe acute respiratory syndrome coronavirus 2,
Communication,
Private Securities Litigation Reform Act,
Hand,
NIH,
U.S. Securities and Exchange Commission,
National Research Council,
COVID-19,
FDA,
Infection,
Immunization,
Pharmaceutical industry,
Oragene Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) today announced it has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that enables Oragenics to pursue an intranasal vaccine designed to protect against future variants of coronaviruses.
Key Points:
- Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) today announced it has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that enables Oragenics to pursue an intranasal vaccine designed to protect against future variants of coronaviruses.
- Oragenics is well-positioned to develop intranasal vaccines against future variants of SARS-CoV-2 thanks to our successful, on-going collaboration with the NRC, said Frederick W. Telling, Ph.D., Oragenics Executive Chairman.
- We had anticipated the need for rapid development of COVID-19 vaccine candidates against new variants and can leverage the NRC cell expression platform to address future variants.
- Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms.
Health,
Infectious Diseases,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Mission statement,
NYSE,
Bacteria,
Research,
NRC,
U.S. Securities and Exchange Commission,
Communication,
Private Securities Litigation Reform Act,
Security (finance),
NYSE American,
NIH,
COVID-19,
Annual report,
Infection,
Audit,
Oragene See further discussion in footnote 1 to the Companys financial statements included in the Companys Annual Report on Form 10-K.
Key Points:
- See further discussion in footnote 1 to the Companys financial statements included in the Companys Annual Report on Form 10-K.
- This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph.
- Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus.
- The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements.
Research,
Infectious Diseases,
FDA,
Clinical Trials,
Biotechnology,
Health,
Pharmaceutical,
Other Science,
Science,
Laboratory,
Drug development,
Patent,
EVP,
Investigational New Drug,
Pharmacokinetics,
Clinical trial,
NYSE,
Toxicology,
GLP,
Contract research organization,
IND,
Vaccine,
Bacteria,
Research,
Biotechnology,
NRC,
Food,
Communication,
Private Securities Litigation Reform Act,
Hand,
NIH,
Rabbit,
U.S. Securities and Exchange Commission,
Goal,
COVID-19,
Frontage,
Regulation of tobacco by the U.S. Food and Drug Administration,
CRO,
Drug discovery,
Infection,
FDA,
Acquisition,
Immunization,
Pharmaceutical industry,
Oragene,
ORAGENICS, INC.,
FRONTAGE LABORATORIES Oragenics has contracted with Frontage Laboratories (through its wholly owned subsidiary Experimur) to conduct the study, with top-line interim data expected in August.
Key Points:
- Oragenics has contracted with Frontage Laboratories (through its wholly owned subsidiary Experimur) to conduct the study, with top-line interim data expected in August.
- With the recent acquisition of Experimur, Frontage is well positioned to support Oragenics development needs through the IND and beyond.
- We are thrilled to have begun this pivotal study with Frontage, a premier drug development contract research organization, and are thankful to the acceleration Frontage has offered our important IND-enabling study.
- We believe the results from this rabbit toxicology study will support our development strategy for our intranasal COVID-19 vaccine candidate, NT-CoV2-1.
Health,
Infectious Diseases,
Manufacturing,
Clinical Trials,
Other Manufacturing,
Pharmaceutical,
Biotechnology,
CHO,
Senior,
Trial of the century,
Private Securities Litigation Reform Act,
Drug development,
IND,
Research,
Partnership,
FDA,
Communication,
U.S. Securities and Exchange Commission,
CDMO,
KBI,
Nose,
Infection,
Hand,
NYSE,
Immunization,
NIH,
COVID-19,
NRC,
Severe acute respiratory syndrome coronavirus 2,
Vaccine,
CGMP,
Bacteria,
Patent,
Fine chemical,
Pharmaceutical industry,
Oragene,
KBI Biopharma, Inc.,
Oragenics, Inc.,
KBI BIOPHARMA, INC.,
ORAGENICS, INC. We are delighted to enter into a development collaboration for our SARS-CoV-2 intranasal vaccine candidate with an outstanding commercial partner.
Key Points:
- We are delighted to enter into a development collaboration for our SARS-CoV-2 intranasal vaccine candidate with an outstanding commercial partner.
- "As a contract manufacturer accelerating the development of innovative discoveries into life-changing biological products, KBI is perfectly positioned for first manufacturing for Oragenics," said Brandon Vail, Senior Vice President, KBI Business Development.
- "KBI is proud of the important role in the continued fight against SARS-CoV-2 through our partnership with Oragenics."
- Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus.
Science,
Biotechnology,
Research,
Pharmaceutical,
Health,
FDA,
Infectious Diseases,
Clinical Trials,
Viral load,
NRC,
Private Securities Litigation Reform Act,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Vaccine,
Research,
Immunization,
Immunoglobulin A,
Food,
U.S. Securities and Exchange Commission,
Immunoglobulin G,
Blood,
Bacteria,
FDA,
Program,
Hand,
NYSE,
COVID-19,
Communication,
Patent,
National Institute,
Infection,
Preprint,
Manuscript,
National Research Council,
Investigational New Drug,
Severe acute respiratory syndrome coronavirus 2,
Antibody,
Nose,
Foundation for the National Institutes of Health,
Mouse,
Oragene Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) today announced the posting of a preprint manuscript in bioRxiv (pronounced bio-archives).
Key Points:
- Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) today announced the posting of a preprint manuscript in bioRxiv (pronounced bio-archives).
- The studies described in the manuscript evaluated a novel spike protein subunit vaccine formulation, NT-CoV2-1, containing a proteosome-based mucosal adjuvant designed for intranasal immunization.
- The studies concluded that intranasal formulation induced robust antigen-specific IgG and IgA titers in the blood and lungs of mice.
- The studies concluded that this intranasal vaccine formulation warrants further development as a novel SARS-CoV-2 vaccine.
Retrieved on:
Wednesday, January 26, 2022
Health,
Infectious Diseases,
Research,
Pharmaceutical,
Science,
Biotechnology,
COVID-19,
NYSE,
Eastern Time Zone,
Proxy,
Suite,
Bank,
National Research Council,
National Institute,
Annual general meeting,
Terra,
Bank of America Plaza,
Research,
SEC,
THE,
Annual Meetings of the International Monetary Fund and the World Bank Group,
Annual,
Company,
Infection,
Telephone,
National Institutes of Health,
Common stock,
U.S. Securities and Exchange Commission,
Security (finance),
Oragene Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) announced that the Companys reconvened Annual Meeting of Shareholders (the Annual Meeting), on January 25, 2022, at 4:00 p.m. was convened and again adjourned, without any business being conducted, due to lack of the required quorum.
Key Points:
- Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) announced that the Companys reconvened Annual Meeting of Shareholders (the Annual Meeting), on January 25, 2022, at 4:00 p.m. was convened and again adjourned, without any business being conducted, due to lack of the required quorum.
- At the time the Annual Meeting was again adjourned, proxies had been submitted by stockholders representing approximately 40% of the shares of the Companys common stock outstanding and entitled to vote at the Annual Meeting.
- In connection with the Annual Meeting, the Company filed a definitive proxy statement with the SEC on October 13, 2021.
- The definitive proxy statement was mailed to shareholders who are entitled to vote at the Annual Meeting.
